Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2005 Jun 1;105(11):4455-62.
doi: 10.1182/blood-2004-05-1699. Epub 2005 Feb 17.

Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP

Affiliations

Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP

Kumudha Balakrishnan et al. Blood. .

Abstract

Myeloid cell leukemia-1 (MCL-1) acts as a key survival factor for chronic lymphocytic leukemia (CLL) cells. In addition, dissipation of cellular bioenergy may impose a lethal effect on these quiescent cells. Previously, in multiple myeloma cell lines we demonstrated that halogenated adenosine (8-Cl-Ado) was phosphorylated to triphosphate (8-Cl-adenosine triphosphate [ATP]), which preferentially incorporated into mRNA and inhibited RNA synthesis by premature transcription termination. Furthermore, 8-Cl-ATP accumulation was associated with a decline in cellular bioenergy. Based on these actions, we hypothesized that 8-Cl-Ado would be ideal to target CLL lymphocytes. In the present study we demonstrate that leukemic lymphocytes incubated with 8-Cl-Ado display time- and dose-dependent increase in the accumulation of 8-Cl-ATP, with a parallel depletion of the endogenous ATP pool. Inhibition of global RNA synthesis resulted in a significant decline in the expression of transcripts with a short half-life such as MCL1. Consistent to this, protein expression of MCL-1 but not B-cell lymphoma-2 (BCL-2) was decreased. Furthermore, 8-Cl-ATP induced programmed cell death, as suggested by caspases activation, cleavage of caspase 3, and PARP (poly-adenosine diphosphate [ADP]-ribose polymerase), and increased DNA fragmentation. In conclusion, 8-Cl-Ado induces apoptosis in CLL lymphocytes by targeting cellular bioenergy as well as RNA transcription and translation of key survival genes such as MCL1.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Structure of 8-Cl-adenosine.
Figure 2.
Figure 2.
Accumulation of 8-Cl-ATP and depletion of ATP pool with the treatment of 8-Cl-Ado in primary CLL cells from 7 patients (1, 3-8). The CLL lymphocytes were incubated with 10 μM 8-Cl-Ado for indicated times and PCA-extracted nucleotides were analyzed by HPLC. The accumulation of 8-Cl-ATP (▴) and the depletion of ATP (•) are plotted together for 7 hours (A) and up to 24 hours (B). Symbols indicate mean ± standard deviation.
Figure 3.
Figure 3.
Dose-dependent accumulation of 8-Cl-ATP and its relation to the ATP pool. CLL lymphocytes from 12 patients (8, 23-33) were incubated with indicated concentration of 8-Cl-Ado for 4 hours and PCA-extracted nucleotides were analyzed by HPLC. Dose-dependent increase of 8-Cl-ATP was plotted (A) and accumulation of 8-Cl-ATP at 30 μM exogenous 8-Cl-Ado was compared with endogenous ATP pool from each patient (B); each symbol represents one patient.
Figure 4.
Figure 4.
Effect of 8-Cl-Ado on expression of antiapoptotic proteins MCL-1 and BCL-2 in CLL lymphocytes. Immunoblot analysis was carried out for the expression of MCL-1 and BCL-2 proteins after incubating CLL lymphocytes with 10 μM 8-Cl-Ado with varying times. Actin was used as a loading control.
Figure 5.
Figure 5.
Induction of CLL cell death by 8-Cl-Ado. Several experimental approaches were used to determine cell death of primary leukemic lymphocytes by 8-Cl-Ado. Immunoblot analysis of cleavage of procaspase 3 to active caspase 3 (A), caspase activation detection by fluorescent assay (B), time-dependent cleavage of PARP (C), and apoptotic death measured by sub GO-G1 DNA content (D).

Similar articles

Cited by

References

    1. Keating MJ. Management of chronic lymphocytic leukemia: a changing field. Rev Clin Exp Hematol. 2002;6: 350-365. - PubMed
    1. Keating MJ, O'Brien S, Lerner S, et al. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998;92: 1165-1171. - PubMed
    1. Flinn IW, Byrd JC, Morrison C, et al. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies. Blood. 2000;96: 71-75. - PubMed
    1. O'Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol. 2001;19: 1414-1420. - PubMed
    1. Boogaerts MA, Van Hoof A, Catovsky D, et al. Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2001;19: 4252-4258. - PubMed

Publication types

MeSH terms